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Abstract This study followed a cohort of 103 patients at
median 6 days, 6 and 16 weeks after stroke and recorded
muscle tone, pain, paresis, Barthel Index and quality of life
score (EQ-5D) to identify risk-factors for development of
spasticity. 24.5% of stroke victims developed an increase
of muscle tone within 2 weeks after stroke. Patients with
spasticity had signiﬁcantly higher incidences of pain and
nursing home placement and lower Barthel and EQ-5D
scores than patients with normal muscle tone. Early pre-
dictive factors for presence of severe spasticity [modiﬁed
Ashworth scale score (MAS) C3] at ﬁnal follow-up were
moderate increase in muscle tone at baseline and/or ﬁrst
follow-up (MAS = 2), low Barthel Index at baseline,
hemispasticity, involvement of more than two joints at ﬁrst
follow-up, and paresis at any assessment point. The study
helps to identify patients at highest risk for permanent and
severe spasticity, and advocates for early treatment in this
group.
Keywords Acute cerebral infarction  Spasticity 
Spasticity related pain  Barthel index  Quality of life
Introduction
Upper motor neuron lesions may raise positive and nega-
tive symptoms [21]. Beside brisk tendon reﬂexes, clonus,
spasms, and dystonia, spasticity is one of the positive
phenomena and results from impaired reﬂex function and
changes in rheologic muscle properties like stiffness,
ﬁbrosis, and atrophy [5]. Contracture is determined by
degenerative changes and an alteration in passive and
contractile properties of the muscle and may potentiate
spasticity [5, 8, 10]. Negative features of upper motor
neuron lesions are loss of selective control of muscles and
limb segments, weakness, and slowness of movement and
are closely interconnected with spasticity [5, 14]. The
functional changes in the affected limbs may cause pain,
dependency, and decline in the quality of a patient’s life
and self esteem.
Despite the severe consequences and high frequency of
upper motor neuron lesions, only a few studies have
addressed the occurrence and temporal evolution of spas-
ticity following stroke [11, 13, 14, 17, 18]. The present
study follows a cohort of patients from the immediate days
after stroke to assess frequency and development of spas-
ticity and identiﬁes risk-factors for development of post-
stroke spasticity.
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The stroke units of the Potsdam and Teupitz hospitals are
both located in the federal state of Brandenburg, Germany,
and serve for approximately 450,000 inhabitants. They
accept all acute stroke patients without any selection. From
April 1st to June 30th, 2006, all consecutive stroke patients
(n = 103) admitted to the hospitals were included in the
study without selection (patient details see Table 1).
To minimize interrater variability all patients were
assessed by the same physiotherapist (J.S.) at baseline and
each follow-up. J.S. is a seasoned physiotherapist with
more than 10 years full-time practice in stroke rehabilita-
tion. He observed consistent examination conditions and
distinguished between spastic, rigid, and dystonic increase
of muscle tone. Patients had their initial examination
within the ﬁrst 2 weeks after admission in the hospital
ward (baseline). After a median of 6 (ﬁrst follow-up) and
16 (second follow-up) weeks, the patients were reinvesti-
gated either in the neighbouring rehabilitation units (Be-
elitz and Potsdam, Brandenburg, Germany) or at the
patient’s private or nursing home (Fig. 1).
Prior to study entry informed consent was required,
either given personally or by an authorized family member.
The study was approved by the Brandenburg ethics
committee.
Assessments
At each visit the muscle tone of the shoulder, elbow, wrist,
hip, knee, and ankle of all affected extremities was quan-
tiﬁed by J.S. with the modiﬁed Ashworth Scale (MAS) [2].
The authors are aware that MAS assessed only an epi-
phenomenon rather than the cause of the functional
condition, but the present study was oriented to the diag-
nostic and not to the functional testing of spasticity [4].
During the study, only one patient obtained an antispastic
treatment of 10 mg oral baclofen per day (ﬁrst and second
assessment, MAS 3 and 4, respectively). The other patients
had no antispastic drugs.
Pain at rest and pain evoked by passive joint movement
was assessed by the 11 point box test. The assessment
referred to the total amount of pain experienced by the
patient, subgroups (musculo-skeletal or neuropathic pain)
were not differentiated. Oral analgesics (NSARs, opioids)
were applied when necessary and continued throughout the
studyinallpatientswithpain.Paresiswasratedaspresentor
absent atbaseline and quantitatively on a 0–3 scale (0 = no,
1 = mild, 2 = moderate, 3 = severe paresis). At second
follow-up.J.S.alsorecordeddeﬁcitsofsensationandneglect
at baseline and second follow-up as present or absent.
Functional disability was assessed by the Barthel Index
at baseline, ﬁrst and second follow-up. The Barthel Index
measures a person’s performance in basic self care. The
maximum score of 100 indicates independency [12, 16].
Quality of life was calculated by the EuroQoL EQ-5D at
each follow-up. The EQ-5D questionnaire is a state of
health measure and describes health condition in mobility,
self care, usual activities, pain/discomfort, and anxiety/
depression, with three levels per attribute (possible range
0–100). A higher score indicates a better quality of life
[1, 7].
Statistical analysis
All variables were analyzed with non-parametric methods.
Changes from baseline were compared with follow-up
visits using the Wilcoxon signed-rank test. Correlation of
paresis with MAS score was calculated by the Mann–
Whitney U Test. The EQ-5D-index sum score was calcu-
lated for each patient as follows: 100- (109 [item1 ? -
item2 ? item3 ? item4 ? item5 - 5]) according to Hinz
et al. [7]. Kruskal–Wallis one-way analysis of variance
(ANOVA) was performed with EQ-5D-index sum score as
dependent variable and paresis, spasticity, and pain as
independent variables.
Results
Baseline
Baseline assessment was performed median 6 days fol-
lowing stroke with a range of 1–14 days. Nine patients
(8.7%) with re-infarction and spasticity (median MAS = 2
[1–3]) were identiﬁed at the baseline examination and were
Table 1 Patient details (n = 103)
Mean age (years) 69 (35–96)
Percentage of patients B60 years 25%
Female 38%
Type of stroke
Ischemia 86%
Hemorrhage 14%
Lesion site
Supratentorial 83%
Infratentorial 15%
Combined 2%
Affected side
Left hemisphere 44%
Right hemisphere 56%
Neglect 15%
Patients with re-infarction 16%
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123excluded from further analysis to avoid interference with
pre-existing spasticity (Fig. 1).
Among the remaining 94 patients, 23 (24.5%) showed
an increase of muscle tone in at least one joint (Fig. 2). The
MAS scores are given in Fig. 1.
Twelve patients (13%) had pain in the extremities
affected by their stroke. Median pain severity was 5 (range
4–10). Pain in patients with raised muscle tone affected the
arm in seven, the leg in two and both arm and leg in three
patients, was present at rest in seven and evoked by passive
stretch in ﬁve patients. Weakness was present in 65% of
patients. 13% of them suffered from tetraparesis, 87% from
hemiparesis.
Patients with increased muscle tone had a signiﬁcantly
lower Barthel Index (median 63.3, range 45–100) than
patients without spasticity (median 80.6, range 45–100;
P = 0.07). The median baseline EQ-5D-index sum score
was 75 (range 40–100). ANOVA showed a signiﬁcant
effect of paresis, increase of muscle tone and pain on
quality of life (P = 0.004).
    d e s s e s s a   . s t p   e k o r t s   3 0 1
  y t i c i t s a p s   g n i t s i x e - e r p   h t i w   d e d u l c x e   . s t p   9  
94 pts. included into the study 
23 pts. (24.5%) with increased 
muscle tone 
Baseline examination 
median 6 (range 1-14) days after stroke 
MAS 1  11 
MAS 1+  4 
MAS 2  8 
S A M (   d e i d   . s t p   8    0/1/2=6/1/1 pts., 
respectively) 
86 pts. at first follow up 
  23 pts. (26.7%) with spasticity 
MAS 1  5 
First follow up 
median 6 (range 4-12) weeks after stroke 
MAS 1+  4 
MAS 2  6 
MAS 3  4 
MAS 4  4 
/ 1 / 0   S A M (   d e i d   . s t p   3   3=1/1/1 pt., respectively)
83 pts. at second follow up 
  18 pts. (21.7%) with spasticity 
MAS 1  7 
Second follow up 
median 16 (range 12-24) weeks after stroke 
MAS 2  3 
MAS 3  2 
MAS 4  6 
Fig. 1 Study population
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123First follow-up
The ﬁrst follow-up assessment was performed median
6 weeks following stroke with a range of 4–12 weeks
(Fig. 1). Eight of the 94 included patients have died since
baseline (9%). Twenty-three of the 86 surviving patients
(26.7%) showed a spastic increase of muscle tone in at
least one joint (Fig. 2). If any spasticity occurred during the
course of the study, it emerged in 98% of the patients up to
the ﬁrst follow-up. The MAS is given in Fig. 1.
Pain in extremities affected by stroke was present in
eight of the 14 patients (57%) with moderate (MAS = 2)
or severe spasticity (MAS C 3). Median Barthel Index was
90 (45–100).
Second follow-up
The second follow-up assessment was performed median
16 weeks following stroke with a range of 12–24 weeks.
Three further patients had died since ﬁrst follow-up (total
of 11, 12%).
Eighteen of the 83 surviving patients at 4 month follow-
up (21.7%) showed an increase of muscle tone in at least
one joint (Fig. 2). The MAS is shown in Fig. 1, the dis-
tribution of spasticity is depicted in Fig. 3. Spasticity
developed most often in elbow, wrist, and ankle.
17% (n = 14) of all patients suffered from pain in
extremities affected by their stroke. Median pain severity
was 5 (range 4–8). Among patients without spasticity only
one out of 65 (1.5%) had pain while 13 of 18 stroke suf-
ferers with spasticity (72%) reported pain (P\0.001)
(Fig. 4). Pain evoked by passive stretch in extremities
affected by stroke was present in 10 of the 11 patients
(91%) with moderate (MAS = 2) or severe spasticity
(MAS C 3) and in three of seven patients (43%) with mild
spasticity (MAS = 1). Spastic arm was painful in nine,
spastic leg in two and spastic arm plus leg in two patients.
Spasticity was associated with pain in the shoulder in 60%,
in the elbow in 100% and in the wrist in 33%. Pain in the
leg was not closely correlated to spasticity.
Weakness was present in 62% of all patients (in 50% of
patients without spasticity and in 100% of those with
spasticity) and was mild in 38%, moderate in 33%, and
severe in 29%. 96% of the weak patients had hemiparesis,
4% were tetraparetic. The mere presence of spasticity did
not correlate with the intensity of paresis (P = 0.2). On the
contrary, when accounting for the degree of spasticity
patients with higher MAS scores at second follow-up had
moderate or severe paresis already at the ﬁrst examination
(P = 0.02).
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Fig. 2 Development of muscle hypertonia during follow-up. Number
of patients with muscular hypertonia at different time points after
stroke (blue fraction of the bar: patients with initial muscle
hypertonia; red fraction of the bar: patients with initial hypertonia,
but not at follow-up; yellow fraction of the bar: additional patients
with muscle hypertonia)
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Fig. 3 Localisation of spasticity in stroke patients at second follow-
up. Numbers indicate percent of patients with spasticity at the
respective joint
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Fig. 4 Frequency and distribution of pain in patients with and
without spasticity at second follow-up. Dotted bars mean patients
without spasticity (MAS = 0), hatched bars show percent of patients
with MAS 1–4
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123Median Barthel Index was 95 (45–100) at second fol-
low-up. Patients with spasticity had signiﬁcantly lower
values than patients without (P = 0.035). Placement in a
nursing home correlated well with the degree of spasticity:
31% of patients with MAS 2–4, but only 13% with MAS
0–1 ? (P\0.05) lived in a facility at second follow-up.
The EQ-5D-index sum score was median 74.6 (range
20–100). Patients without spasticity had a median of 80.6
points, while the score in patients with spasticity was
median 63.3 (P = 0.07).
Prognostic factors in the development of spasticity
(Table 2)
Early moderate increased muscle tone predicted spasticity
at follow-up: MAS of 2 in at least one joint within the ﬁrst
2 weeks after stroke was only found in patients who had
spasticity at the second follow-up (one patient with
MAS = 1 and four patients with MAS C 2). All patients
with severe spasticity (MAS C 3, n = 8) at second follow-
up had a MAS of two or higher in at least one joint up to
the sixth week after stroke (P = 0.01). Patients with
spasticity at second follow-up had involvement of median
3.5 joints, while patients with eventual recovery had
median two joints affected.
Patients without paresis at the ﬁrst or second follow-up
never developed spasticity. Severity of paresis at the sec-
ond follow-up was signiﬁcantly correlated with degree of
spasticity (P = 0.02). Presence of hemiparesis correlated
well with spasticity at ﬁrst (P = 0.02) and second
(P = 0.005) follow-up. Lower Barthel Index at baseline
predicted development of more severe spasticity at ﬁnal
follow-up (P = 0.002). None of the baseline factors such
as age, sex, location, or type of stroke or smoking history
was signiﬁcantly associated with the development of
spasticity in this sample.
Ten patients with initial increase of muscle tone were
free from spasticity at the second follow-up. In nine of
them only the arm and a median of two joints were affected
with low degrees of spasticity (MAS = 1), while only one
patient with initial hemispasticity had eventual
normalisation of muscle tone. No difference in age, sex,
stroke localisation, smoking history, and Barthel Index at
baseline was found between patients with sustained spas-
ticity and those eventually recovered.
The typical patient with high risk for permanent spas-
ticity showed hemispasticity with emphasis on the arm,
more than two joints affected, and MAS scores of 2 or
higher up to ﬁrst follow-up (Table 2).
Discussion
The strength of this prospective observational study is the
high quality of data. The same investigator assessed all
patients consecutively, and therefore no interrater vari-
ability needs to be considered. Twenty-three patients
experienced increased muscle tone within the ﬁrst 2 weeks
following stroke, and eight of them already had a MAS of 2.
Like the other studies we found the highest incidence of
spasticity affecting the joints of the arm [11, 14]. Patients
with equal or greater MAS 2 at second follow-up were
affected by concomitant signiﬁcantly lower Barthel Index
scores, lower quality of life, and more pain. Pain developed
within the ﬁrst 12 weeks after stroke and nearly exclusively
emerged in patients with spastic increase of muscle tone.
As described by Sommerfeld et al. [14] we found
spasticity in patients at second follow-up who had no
spastic muscle tone initially, as well as patients with nor-
mal muscle tone at the ﬁnal assessment who were initially
spastic (Fig. 2). Increased muscle tone affecting three or
more joints and MAS of 2 or higher in one of the affected
joints at baseline or within the ﬁrst 6 weeks following
stroke were associated with severe disabling spasticity at
second follow-up. The degree of paresis at the second
follow-up was closely related to the degree of spasticity. A
lower Barthel Index at baseline predicted higher spasticity
at second follow-up, which was also reported by Lund-
strom et al. [11]. Other early risk-factors indicating later
development of spasticity were not identiﬁed in this study.
Until now only a few studies have dealt with the tem-
poral evolution of spasticity after stroke, and most of them
surveyed subjects only once and only months after stroke.
Several early studies investigated small numbers of
patients at different single time points after stroke from one
to 76 months, respectively. They stated that spasticity was
rarely apparent during the ﬁrst month following stroke but
reached its peak 1–3 months after stroke [3, 6, 9, 13, 15]. A
spasticity incidence of 39% was reported at 12 months by
Watkins et al. [17]. This study examined only 106/270
patients of the initial sample; maybe this is the reason for
the unusually high proportion of spastic subjects in com-
parison with the numbers encountered in other studies.
Sommerfeld et al. [14] assessed their cohort after a mean of
Table 2 Risk factors for development of permanent spasticity
Feature P value
Any paresis in affected limb \0.001
More severe paresis at median 16 weeks 0.02
MAS C 2 in at least one joint within median 6 weeks
after stroke
0.01
More than two joints affected by increased muscle tone 0.002
Hemispasticity within median 6 weeks after stroke 0.01
Lower Barthel Index at baseline 0.002
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1235 days after stroke and found 21% of her patients mildly
spastic (MAS 1 and 2), while 3 months later 19% had
spasticity. After 18 months Welmer et al. [18] found 19%
spasticity in their sample in a follow-up study. Lundstrom
et al. [11] estimated a prevalence of 17% of any spasticity
1 year after ﬁrst-ever stroke. Following the deﬁnition of
disability of the WHO International classiﬁcation of func-
tion, disability and health concept [20], disabling spasticity
emerged with a prevalence of 4% in the Lundstrom sample
at 12 months. The present study conﬁrmed the increase in
muscle tone within the ﬁrst days up to 6 weeks after stroke
at close follow-up intervals and found similar numbers of
patients affected (24.5%).
The rationale of antispastic treatment has changed over
the last 20 years. Dietz noted that therapeutic options are
limited in spastic movement disorders and leave the doctor
somewhat resourceless [4]. Because the increased stiffness
of a muscle to stretch results from changes in connective
tissue, reduced contractility of muscle ﬁbres, and sub-
clinical contractures due to a loss of sarcomeres, antispastic
medication directed against exaggerated reﬂexes and
increased tone will fail to produce functionally relevant
improvement of the disturbed movement [5]. Physiother-
apy with focus on training of residual motor function,
relearning, and activation is the most promising interven-
tion to gain function and to prevent secondary complica-
tions [6, 16]. Medical antispastic interventions may reduce
muscle tone and painful spasms in the non-ambulatory
patient and thereby improve hand or groin hygiene,
dressing hampered by abnormal limb posture, wheelchair
seating and transferring. Prevention of pressure sores and
heterotopic calciﬁcation is vital.
If the decision on physiotherapeutic or pharmaceutic
antispastic treatment is reached in the individual patient,
the present study advocates early treatment and helps to
identify the patient group at highest risk for severe future
spasticity. Supportive treatment of spasticity increasingly
relies on injection of botulinum toxin into spastic muscles
[19]. A prospective, placebo controlled trial will follow the
present study to assess the effect of early intervention with
botulinum toxin on development of later spasticity, phys-
iotherapeutic training and quality of life in these at-risk
post-stroke patients.
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